NCT06540378Completed
Stiripentol for the Treatment of Refractory Status Epilepticus
Source: ClinicalTrials.gov · Last updated 6 Aug 2024
Brief summary (registry, in English)
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who received additional treatment of SE with STP. All patients who received STP during the SE were included, regardless of previous medication.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25 (actual)
- First submitted
- 30 Jul 2024
- Start date
- 1 Jan 2013
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- University Hospital Marburg
- Diseases
- Epilepsy
- NCT number
- NCT06540378
What you commit to
- Study type: Observational
- Participants enrolled: 25
- From 1 Jan 2013 to the primary completion date, 31 Dec 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- children
Who the study is looking for
- adult patients who suffered from RSE or SRSE and received STP as add on therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.